Outlook Magazine, Autumn 2016 by unknown
Washington University School of Medicine
Digital Commons@Becker
Outlook Magazine Washington University Publications
2016
Outlook Magazine, Autumn 2016
Follow this and additional works at: https://digitalcommons.wustl.edu/outlook
This Article is brought to you for free and open access by the Washington University Publications at Digital Commons@Becker. It has been accepted
for inclusion in Outlook Magazine by an authorized administrator of Digital Commons@Becker. For more information, please contact
engeszer@wustl.edu.
Recommended Citation
Outlook Magazine, Autumn 2016. Central Administration, Medical Public Affairs. Bernard Becker Medical Library Archives.
Washington University School of Medicine, Saint Louis, Missouri. https://digitalcommons.wustl.edu/outlook/194
outlook.wustl.edu Outlook  3
A U T U M N  2 0 1 6OUTLOOK.WUSTL.EDU
F I G H T I N G  S U P E R B U G S    Q & A  W I T H  N E W  D E A N    F O S T E R I N G  S T U D E N T  R E S E A R C H
Evidence-based program 
transforms physical therapy
Redefining         
   movement
163262_OFC-OBC_cc15.indd  3 9/1/16  4:20 PM
COVER   Physical therapy researchers  
use advanced technology to study 
movement in patients. More than 
three decades ago, the evidence-based 
Program in Physical Therapy adopted 
the movement system as a central  
tenet and has lobbied steadily for its 
national acceptance. Story on page 8. 
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Associate Dean Koong-Nah Chung, 
PhD (left), takes a personal interest 
in medical student research. Story 
on page 20.
A three-drug cocktail given in mice 
overwhelmed the defenses of the notorious 
methicillin-resistant Staphylococcus aureus 
(MRSA), shown above. Story on page 14.
In 1963, Tom Hornbein, MD ’56 (left), 
and fellow climber Willi Unsoeld 
completed the first successful ascent 
of Mount Everest via the West Ridge. 
Familiar with overcoming very 
big obstacles and achieving goals, 
Hornbein was uniquely qualified to 
address students at this year’s MD 
Commencement. Story on page 31.
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T he human brain has remained largely uncharted, but a detailed new map by Washington 
University researchers lays out the 
landscape of the cerebral cortex — the 
dominant structure involved in sensory 
perception, attention, language, tool use 
 and abstract thinking.
The map divides both the left and right  
cerebral hemispheres into 180 areas based 
on physical differences, functional distinctions 
and variations in the connections.
The researchers drew upon data and 
methods generated by the Human 
Connectome Project (HCP), a five-year, 
multimillion dollar study led by David Van 
Essen, PhD, the Alumni Endowed Professor 
of Neuroscience, and involving a consortium 
that includes the University of Minnesota 
and Oxford University. The HCP used a 
powerful, custom-built MRI machine to 
map the brains of 1,200 young adults.
To make this new map, the study’s lead 
author Matthew Glasser, PhD, Van Essen 
and colleagues pooled data from 210 
healthy young adults. The researchers 
combined measures of the thickness of  
the cortex and the amount of insulation 
around neuronal cables, with MRI scans  
of the brain at rest and while performing 
simple tasks, such as listening to a story.
 “We ended up with 180 areas in each 
hemisphere, but we don’t expect that to be 
the final number,” Glasser said. “In some 
cases, we identified a patch of cortex that 
probably could be subdivided, but we 
couldn’t confidently draw borders with our 
current data and techniques. In the future, 
researchers with better methods will 
subdivide that area. We focused on borders 
we are confident will stand the test of time.”
The researchers improved on previous 
maps by aligning the brains to a common 
coordinate system before analysis, using  
an algorithm developed by colleagues at 
Oxford University, and incorporating the 
highest-quality MRI data available.
The results are a precise map with  
crisp borders and an algorithm capable of 
locating the areas in individual brains, even 
though each individual is unique in terms 
of the pattern of cortical folds and in the 
size and shape of areas on the cortical map.
The work is available online in Nature, 
including 200 pages of detailed information 
on each of the 180 regions and algorithms 
used. “We think it will serve the scientific 
community best if they can dive down  
and get these maps onto their computer 
screens and explore as they see fit,” 
 Van Essen said.
pulse
David Van Essen, PhD (left), and Matthew Glasser, 
PhD, are part of a team that mapped the human 
cerebral cortex in painstaking detail. The map will 
help researchers study brain disorders such as autism, 
schizophrenia, dementia and epilepsy.
The map divides both  
the left and right cerebral  








Map provides detailed picture  
of how the brain is organized
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DEVELOPMENTAL STUDY   Preemies whose daily 
diets were at least 50 percent breast milk had more brain tissue 
and cortical surface area by their due dates than premature 
babies who consumed significantly less breast milk. Led by 
Cynthia Rogers, MD, assistant professor of child psychiatry, the 
researchers retrospectively studied how much breast milk 77 
preterm babies received while in the Neonatal Intensive Care 
Unit (NICU) at St. Louis Children’s Hospital, then conducted 
brain scans at about the time of their full-term due dates. 
Signaling a potential new approach to treating diabetes, 
researchers at the School of Medicine and Harvard 
University have produced insulin-secreting cells from  
stem cells derived from patients with type 1 diabetes.
e discovery suggests a personalized treatment approach 
may be on the horizon — one that relies on the patients’ own 
stem cells to manufacture new cells that make insulin.
e researchers showed that the new cells could produce 
insulin when they encountered sugar. e scientists tested 
the cells in culture and in mice, and in both cases found 
that the cells secreted insulin in response to glucose.
 “In theory, if we could replace the damaged cells in 
these individuals with new pancreatic beta cells — whose 
primary function is to store and release insulin to control 
blood glucose — patients 
with type 1 diabetes 
wouldn’t need insulin 
shots anymore,” said 
rst author Jerey  
R. Millman, PhD, an 
assistant professor  
of medicine and  
of biomedical 
engineering at the 
School of Medicine.
Millman, whose 
laboratory is in 
the Division of 
Endocrinology, Metabolism and Lipid Research, began 
his research in the laboratory of Douglas A. Melton, 
PhD, Howard Hughes Medical Institute investigator and 
a co-director of Harvard’s Stem Cell Institute. ere, 
Millman had used similar techniques to make beta cells 
from stem cells derived from people who did not have 
diabetes. In these new experiments, the beta cells came 
from tissue taken from the skin of diabetes patients.
More research is needed to make sure that the beta cells 
made from patient-derived stem cells don’t cause tumors to 
develop — a problem that has surfaced in some stem cell 
research — but there has been no evidence of tumors in the 
mouse studies, even up to a year aer the cells were implanted.
Stem cell-derived beta cells could be ready for human 
research in three to ve years. At that time, Millman expects 
the cells would be implanted under the skin of diabetes 
patients in a minimally invasive surgical procedure that 
would allow the beta cells access to a patient’s blood supply.
Insulin-secreting cells 
created from stem cells
From analyzing vast DNA sequences to handling electronic 
medical records, the importance of big data in medicine has 
increased dramatically in recent years. To support the need to 
manage and harness big data, the medical school has launched 
an Institute for Informatics, naming 
Philip R.O. Payne, PhD, as director.
e school has a long history of 
strong informatics research, which has 
allowed Washington University to take 
important leadership roles in national 
bioinformatics eorts, including the 
Human Genome Project, the Human 
Connectome Project and the very recent 
eorts to understand the microbiome.
e institute will coordinate infor-
matics eorts across the Medical Campus and partner with 
the School of Engineering and Applied Science, the Institute 
for Public Health, the Brown School, the Olin Business 
School, the Innovations Incubator at BJC HealthCare and 
the Cortex Innovation Community.
Payne, formerly chair of the Department of Biomedical 
Informatics at e Ohio State University, is an elected fellow 
of the American College of Medical Informatics. He has 
written more than 175 peer-reviewed articles, book chapters, 
abstracts, editorials and technical reports in his eld.
New Institute for Informatics  
to coordinate big data efforts
Philip R.O. Payne, PhD
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A person’s genetic makeup plays a role in autoimmune 
diseases that develop when the body is attacked by its  
own immune system. But little is known about how  
genetic variations push immune cells into overdrive.
Now, School of Medicine researchers have identied 
genetic master switches that turn up — or down — the 
activity of specic types of immune cells. e study is 
available online in Cell.
Surprisingly, the DNA regions that make up these  
master switches include numerous genetic variants  
linked to a range of autoimmune diseases.  
“In some cases, 
individual variations 
in a person’s DNA 
probably tweak the  
settings of these 
switches upward, 
leading to over-
activation of the 
immune cells and 
autoimmune disease,” 
said Eugene Oltz, 
PhD, a professor of 
pathology and immunology and study co-senior author.
e researchers compared gene activity in two kinds  
of immune cells — innate lymphoid cells and T helper 
cells — that both serve as “control towers” for the immune 
response, sending out powerful molecular signals to other 
immune cells to start killing invading microbes and 
destroying infected human cells.
e researchers dened a set of super-enhancers — regions  
of DNA that serve as master control switches — for these 
immune cell types. e super-enhancers contain many 
genetic variants associated with autoimmune diseases  
such as diabetes, rheumatoid arthritis, Crohn’s disease  
and ulcerative colitis.
“Geneticists have identied lots of DNA sequence 
variations associated with autoimmune diseases, but it 
wasn’t clear how they were involved because they weren’t in 
any genes known to be involved in the development of these 
diseases,” said co-senior author Marco Colonna, MD, the 
Robert Rock Belliveau, MD, Professor of Pathology. “Now 
that we know where the master switches are, we can see 
that those variants are associated with autoimmune disease 
because they aect the regulation of these immune cells.”
e discovery could lead to personalized therapies targeted 
to the genes regulated by each specic super-enhancer.
Master switches turn up 
immune cell activity 
STUDENT PLEDGE  During orientation, the 124 
incoming students collectively wrote a class oath representing  
their ethics, values and goals. The oath-building tradition 
began more than a decade ago and, with each class, a 
different focus emerges. This year, students emphasized the 
individual patient relationship. The class recited its oath at 
the White Coat Ceremony, a rite of passage in which new 
students receive their coats in front of family and friends. 
I pledge that my patient will always be my 
foremost consideration as I strive to promote 
health and quality of life through education, 
prevention and care.













Super-enhancers found in DNA
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Super-enhancers found in DNA
 buildup of plaque and 
dysfunctional proteins in the 
brain are hallmarks of Alzheimer’s 
disease. While much Alzheimer’s research 
has focused on accumulation of the protein 
amyloid beta, researchers have begun to pay 
closer attention to another protein, tau, long 
associated with this disease but not studied 
as thoroughly, in part, because scientists only 
recently have developed effective ways to 
image tau.
Using a new imaging agent that binds to 
tau protein and makes it visible in positron 
emission tomography (PET) scans, School of 
Medicine scientists have shown that measures 
of tau are better markers of the cognitive 
decline characteristic of Alzheimer’s than 
measures of amyloid beta seen in PET scans.
A study comparing 36 control  
participants who were cognitively normal  
and 10 patients with mild Alzheimer’s 
disease was published May 11 in the  
journal Science Translational Medicine.
 “Our work and that of others has shown 
that elevated levels of amyloid beta are the 
earliest markers of developing Alzheimer’s 
disease,” said senior author Beau M. Ances, 
MD, PhD, an associate professor of neurology. 
“But in the earliest stages of Alzheimer’s 
disease, even with amyloid buildup, many 
Alzheimer’s decline linked to tau protein
A
patients are cognitively normal, meaning their 
memory and thought processes are still intact. 
What we suspect is that amyloid changes first 
and then tau, and it’s the combination of both 
that tips the patient from being asymptomatic 
to showing mild cognitive impairment.”
While Ances called for larger follow-up 
studies, he said this analysis helped establish 
that the new tau agent, called T807, is an 
important tool for understanding the timeline 
of Alzheimer’s progression and for defining 
which regions of the brain are involved. These 
findings could lead to earlier diagnoses and 
clinical trials to test drugs against amyloid 
and tau buildup.
“While we currently cannot prevent or 
cure Alzheimer’s disease, delaying the onset 
of symptoms by 10-15 years would make 
a huge difference to our patients, to their 
families and caregivers, and to the global 
economy,” Ances said.
The Next Century
A Becker Medical Library 
Photovoice Project
Share your (photo)voice: For more than 100 years, 
the people of Washington University School of 
Medicine and Barnes-Jewish and St. Louis Children’s 
hospitals have worked together to advance  
medicine, educate the next generation, and care  
for patients in St. Louis and beyond. To celebrate  
a century of collaboration, Bernard Becker Medical 
Library has launched an online collection of  
inspirational stories and photos. Those with  
ties to Washington University Medical Center are 
invited to take part at photovoice.wustl.edu.
PET scans show average tau accumulation in  
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Commonly touted as “good cholesterol” for helping to 
reduce risk of stroke and heart attack, both high and low 
levels of high-density lipoprotein (HDL) cholesterol may 
increase a person’s risk of premature death, according 
to new research at the School of Medicine and Veterans 
Aairs (VA) St. Louis Health Care System.
Conversely, intermediate HDL cholesterol levels may 
increase longevity, according to the research. e large-
scale epidemiological study is published in the Clinical 
Journal of the American 
Society of Nephrology.
“e ndings surprised 
us,” said Ziyad Al-Aly, 
MD, an assistant professor 
of medicine and the 
study’s senior author. 
“e relationship between 
increased levels of HDL 
cholesterol and early 
death is unexpected and 
not fully clear yet. is will require further study.”
For years, HDL cholesterol has been credited with helping 
to remove plaque-building “bad cholesterol” from arteries.
For this study, researchers studied kidney function 
and HDL cholesterol levels in more than 1.7 million male 
veterans from October 2003 through September 2004, and 
then followed participants until September 2013.
e study showed that both high and low HDL 
cholesterol levels were associated with an increased risk of 
dying among study participants with all levels of kidney 
function. Research data showed a relationship between HDL 
cholesterol levels and mortality as a U-shaped curve with 
the risk of death increased at both ends of the spectrum. 
“e ndings may explain why clinical trials aimed at 
increasing HDL cholesterol levels failed to show improved 
outcomes,” said Al-Aly, who also is the VA’s associate chief 
of sta for research and education and co-director of its 
Clinical Epidemiology Center in St. Louis.
Such ndings regarding HDL cholesterol and premature 
death have not been reported in other large epidemiologic 
studies, Al-Aly said.
“However, the previous studies are limited in that the 
number of patients in those cohorts is relatively small 
compared with what a big data approach enabled us to 
see in our new research,” he said. “Big data allow a more 
nuanced examination of the relationship between HDL 
cholesterol and risk of death across the full spectrum of 
HDL cholesterol levels.”
‘Good cholesterol’ may 
cause premature death
Two scientists at the School of 
Medicine are among the 84 members 
and 21 foreign associates elected to 
the National Academy of Sciences 
this year. Election to the academy — 
which was announced May 3 — is 
considered one of the highest honors 
that can be awarded to a U.S. scientist 
or engineer.
e university’s newest academy  
members are: Kenneth M. Murphy, 
MD, PhD, the Eugene Opie Centennial 
Professor of Pathology and Immunology  
and a Howard Hughes Medical 
Institute investigator; and Herbert 
W. “Skip” Virgin IV, MD, PhD, the 
Edward Mallinckrodt Professor and 
head of the Department of Pathology 
and Immunology.
National Academy members elected
Kenneth M. Murphy, 
MD, PhD
Herbert W. “Skip” 













USE SPARINGLY  Prolonged use of drugs to treat 
heartburn, ulcers and acid reflux may lead to serious  
kidney damage, including kidney failure, according to 
a large five-year study at the School of Medicine and 
Veterans Affairs St. Louis Health Care System. More than 
15 million Americans have prescriptions for so-called 
proton pump inhibitors (PPIs), which generally have been 
considered safe. The medications are sold under brand 
names Prevacid, Prilosec, Nexium and Protonix, among 
others. The epidemiological study is online in the Journal 
of the American Society of Nephrology. The researchers 
called for further study about the safety of PPIs.
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M ice that vocalize in a repetitive, halting pattern similar to human stuttering 
may provide insight into a condition that has 
perplexed scientists for centuries, according 
to researchers at the School of Medicine and 
the National Institutes of Health (NIH).
Initially attributed to nervousness, 
stress or even bad parenting, stuttering is 
now recognized as primarily biological in 
origin, although anxiety can exacerbate 
the condition.
Some people who stutter have a 
mutation in a gene called Gnptab (for 
N-acetylglucosamine-1-phosphate 
transferase alpha and beta). With  
Dennis Drayna, PhD, and colleagues at  
the National Institute on Deafness 
and Other Communication Disorders, 
the researchers created mice with a 
corresponding mutation in the same gene.
These mice vocalized in an abnormal 
pattern characteristic of human stuttering. 
The animal model of stuttering can help 
scientists understand the molecular and 
neurological basis of the disorder, and 
potentially develop treatments.
“Speech is obviously a unique human 
capacity, but the patterns of speech are 
built out of simpler building blocks,” said 
Tim Holy, PhD, an associate professor of 
neuroscience and the paper’s senior author. 
A key characteristic of stuttering is the 
presence of hesitations. The researchers 
developed an algorithm to analyze the 
length of pauses in the spontaneous 
vocalizations of 3- to 8-day-old mouse 
pups. They found that mice carrying the 
mutation exhibited longer pauses than 
those without the mutation.
The researchers applied the same 
algorithm to recordings of people talking, 
some of whom stuttered and some of 
whom did not. The algorithm accurately 
distinguished the two groups.
Other than in their vocalizations, the 
mice with the mutation were normal. In this 
respect, the mice with the mutation are  
like people who stutter — indistinguishable  
from nonstutterers in all but speech.
It is not clear how the gene relates to 
speech. It is known to be involved in the 
pathway that degrades molecules inside 
the cell.
“It could be that the mutation very 
mildly compromises the function of the 
protein, but there’s a set of cells in the brain 
that is exquisitely sensitive, and if you ever 
so slightly compromise the function in those 
cells you get the observable behavioral 
deficit,” said Holy. “We just don’t know yet.”















Senior scientist Terra Barnes, PhD, and Tim Holy, PhD, 
associate professor of neuroscience, hold mouse pups. 
From left to right: Mary Danielson, Tiffany Quan, Tiffany Son, Ailis Powderly, Laura J. Bierut, 
MD, Foluso Ademuyiwa, MD, Tricia Salyer, Laura Muller and Karien Dixon .
Medical and undergraduate  students are recruiting African-
American breast cancer patients for 
a research project on genetic risks. 
Historically, African-American women 
are underrepresented in genetic studies 
of breast cancer. The study, led by Laura 
J. Bierut, MD, Alumni Endowed Professor 
of Psychiatry, and Foluso Ademuyiwa, 
MD, assistant professor of medicine, is 
examining the distribution of mutations 
in genes known to increase cancer risk. 
The hands-on experience is teaching 




163262_2-7_Pulse_cc15.indd  7 8/26/16  10:43 PM











Using advanced technology, physical 
therapy and orthopedic surgery 
researchers Michael Harris, PhD, and 
Marcie Harris-Hayes, PT, DPT, MSCI, 
study movement in 3D. Cameras 
with near-infrared light capture 
motion-reflective markers placed on 
patients with musculoskeletal and 
neuromuscular disorders.
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Walking, rising from a chair, reaching for a book — 
all are simple, everyday movements that many of us 
take for granted. But for the faculty of Washington 
University’s Program in Physical erapy, movement  
is not something to be taken lightly; it is a central  
tenet of health.
e physical therapy (PT) program is a national 
leader in the study of movement and how improper 
movement leads to injury and impairment. With an 
emphasis on diagnosing — rather than simply treating 
patients — the program is changing the way the 
profession is viewed.
More than three decades ago, faculty members 
implemented, and have continued to rene, the 
“movement system” as the basis for the program’s 
research, educational and patient care initiatives.  
“At Washington University the movement system  
really is at the core of all that we do,” said Program 
Director Gammon Earhart, PT, PhD. “at is unique 
relative to most other physical therapy programs. 
Movement 
redened
By adopting movement science as a central tenet, the 
Program in Physical Therapy has reshaped its profession.
B Y  G A I A  R E M E R O W S K I
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 ur goal is to better understand how the     
 movement system works in health and 
disease and to understand what we as physical 
therapists can do to intervene and optimize 
people’s function through movement,” she added.
In 2013, the American Physical erapy 
Association (APTA), the leading PT organization, 
announced it also had adopted the movement 
system as the foundation for the profession. 
The human 
movement system
Just as neurologists are dened  
by their study of the nervous 
system or cardiologists by their 
focus on the heart, PT program 
leaders believe physical 
therapists should be dened 
by their study of the movement 
system. e program denes 
the human movement system 
as a collection of body systems 
(pulmonary, cardiovascular, endocrine, 
nervous and musculoskeletal) that interact 
to produce and support movement. Shirley 
Sahrmann, PT, PhD, FAPTA, professor emerita 
of physical therapy, has developed and promoted 
the human movement system both in Washington 
University’s program and in the profession. 
As an active, athletic kid who grew up in the 
polio era, Sahrmann was deeply aected by stories 
of people who couldn’t participate in sports or 
even walk. She has devoted her 50-year career to 
understanding movement and helping people stay 
as active as possible throughout their entire lives.
Early on, Sahrmann realized she could reduce 
pain in patients with musculoskeletal issues by 
adjusting their movements. “I had to pay a lot 
more attention to why patients were not moving 
correctly,” Sahrmann said. is prompted the  
need for standardized exams and more accurate  
methods to research and measure movement, 
which were lacking in the school’s PT program  
at the time. 
So Sahrmann literally wrote the book on the 
movement system — actually two books, both of 
which are used in the program’s classes and by 
health-care professionals worldwide. Sahrmann 
and others have pushed the eld to adopt and 
associate itself with the movement system. 
With the help of her colleagues, she succeeded  
in getting a denition of the movement system  
into Steadman’s Medical Dictionary and  
continued to lobby for its implementation  
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Over the years, the Washington University 
program has standardized ways to research and  
diagnose various movement impairment disorders  
outlined by Sahrmann and others. Sahrmann’s 
textbooks, considered the gold standard for 
movement system impairment diagnoses, 
contain precise diagnostic terminology. 
However, some of the more than 200,000 
licensed PTs in the U.S. today are working  
within their own diagnostic frameworks, 
resulting in confusion. For example, universities 
that study movement might label their work 
as “biomechanics” or “pathokinesiology” (the 
study of abnormal movements), rather than 
Washington University’s term “movement 
impairments.” is is one reason why the  
profession needs a uniform classication  
system, said APTA President Sharon Dunn,  
PT, PhD, OCS. 
Despite adoption by the APTA in 2013, there 
are still challenges in getting movement system 
diagnoses to the patient level and developing a 
nomenclature that is backed by science. Dunn 
noted that Washington University’s program is 
leading the way and improving patient care.
Diagnosis vs. treatment
With most injuries, patients must rst see a 
medical doctor before consulting a physical  
therapist. e doctor makes a diagnosis such as 
“low back pain” and refers the patient for therapy 
services. Traditionally, PTs have used treatments 
such as massage, heat and exercise to help ease  
the patient’s pain and restore mobility. In this 
longstanding scenario, PTs treat, rather than  
diagnose, their patients. 
Faculty members at the School of Medicine  
are working to change this limited view of  
PTs as treatment technicians, advocating 
they instead should be seen as diagnosis-based 
practitioners with deep expertise in the eld  
of movement science. e movement system 
provides the framework for PTs to establish  
themselves as movement impairment diagnosticians. 
For example, Sahrmann said, “low back pain” 
is not a diagnosis; it is a symptom. e underlying 
cause still must be determined. “You can make 
people feel better immediately,” Sahrmann said, 
“but they’re going to come right back because  
relief doesn’t last unless you really get to the root  
of the problem. 
“Acute pain problems oen are just the rst 
warning of a more progressive issue.” 
Above left: Gammon Earhart, 
PT, PhD (left), director of the 
Program in Physical Therapy, 
and Jennifer Stith, PT, PhD, 
LCSW, director of education, 
meet in the recently reno-
vated student lounge that 
moved from the basement 
to the top floor of the 4444 
Forest Park Building. 
Above: Recent PT graduate  
John Huang performs a  
practice exam on medical  
student Christine Averill,  
while Associate Professor 
Suzanne Cornbleet, PT, DPT, 
observes. The majority of  
faculty who teach clinical 
courses also are actively 
engaged in clinical care. 
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Autumn 201612  Washington University School of Medicine
Oen the root of musculoskeletal pain stems 
from repeated incorrect movement in a patient’s 
everyday activities such as sitting, liing and 
walking. Proper diagnosis requires a thorough 
exam that takes into account a person’s natural 
way of moving. 
Following an exam, a physical therapist might 
change the “low back pain” diagnosis to “lumbar 
exion syndrome,” a condition in which the low 
back is more exible than the hips, causing 
movement imbalances. “So we go through our 
well established movement diagnostic tests and 
we show the patient that if you bend in your hips 
and not in your back, you don’t get symptoms,” 
Sahrmann said.
Upon understanding the cause of movement 
impairments, a trained PT can demonstrate the 
correct way to perform regular activities.
Washington University studies show that 
patients continue performing these types of 
everyday life exercises more oen than ones that 
fall outside of normal routines. Patients are more 
likely to practice the proper way to get up from 
a chair — something they must do on a regular 
basis — than perform specic low back stretches 
requiring them to lie on a mat. 
Sahrmann also argues the physician referral  
requirement needs to change. Many states require 
physician referral for therapy, though some states, 
including Arizona, Iowa, Kentucky, Maryland, 
Massachusetts and Vermont, have moved toward a 
self-referral model. Missouri has yet to follow suit.
John Metzler, MD, an associate professor  
of orthopaedic surgery and of neurology who 
refers many patients to Washington University for 
physical therapy, wholeheartedly agrees that PTs 
are more than technicians. “Most physical therapists  
have a much broader knowledge of musculoskeletal 
problems than the average physician because that’s  
their area of expertise,” he said. “Washington 
University has excellent therapists who are 
methodical in how they approach patients. ey 
have a very systematic way of evaluating how 
patients move, then trying to correct those  
movements and giving very directed exercises.” 
Metzler credits the program’s strong research 
focus and evidence-based practices. 
Moving research forward 
Movement science research is a key part of 
Washington University’s program, which is one  
of the top-funded in the country. In 2015, the  
program received more than $3.5 million in 
research funding, said Michael Mueller, PT, 
PhD, FAPTA, the program’s director of research. 
According to the Web of Science, an industry 
index that compiles publication citation statistics, 
the program also had more papers cited than any 
other PT program in the U.S.
 “All of our research relates in some way to 
movement,” said Earhart, who, as president of  
the APTA section on research, helps translate  
the program’s research results into practice. 
Program research ranges from basic studies of 
how movement occurs on a cellular level all the 
way to a systems level. 
For example, researcher Todd Cade, PT, PhD, 
is looking at muscle metabolism and function in 
patients with Barth Syndrome, a genetic disorder 
that leaves suerers weak and unable to exercise.  
Earhart is leading studies that examine the 
eects of dance and other exercise on improving 
Parkinson’s disease symptoms. Other trials, such 
as a study led by Linda Van Dillen, PT, PhD, are 
exploring the eects of training people with low 
back pain to modify their movement during daily 
activities versus having them perform traditional 
strength and exibility exercises.
Professor Emerita of Physical Therapy Shirley Sahrmann, PT, PhD, FAPTA (left), 
has written two textbooks on movement system impairments that are referenced 
worldwide. Former student Maiko Morotani, PT ’05, translated one of the books 
from English to Japanese and recently traveled with Sahrmann to Japan.
The program has ranked in the 
top 1 percent for two decades.
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Physical therapy  clinic associate Jesse  
Civello, PT, DPT (right), 
uses standardized exams 
developed at Washington 
University to determine 
whether or not a patient 
has a movement  
impairment disorder.
Educational benefits 
is research focus is one of the many educational 
benets for students, Earhart said. “We are able 
to attract outstanding students who are drawn to 
Washington University because of an environment 
that has a research-intensive focus with faculty 
who are internationally and nationally recognized  
for their contributions to the literature and the 
evidence base for physical therapy,” she added. 
Currently ranked No. 1 in the country by U.S. 
News & World Report, the program has been in 
the top 1 percent for two decades.  
Today, all students in the program complete 
a doctorate in physical therapy (DPT). But this 
wasn’t always the case. Susan Deusinger, PT, PhD,  
FAPTA, who retired in 2014 aer 26 years as 
program director, led Washington University’s 
progression from a baccalaureate-level educational  
program to a DPT track, which takes about 
three years and combines clinical, research and 
classroom learning. More recently, the APTA  
has mandated that all academic PT programs 
oer the DPT, a prerequisite to becoming a 
practicing therapist. 
Another major draw for students is the  
program’s clinical practice, staed primarily 
by faculty, said Beth Crowner, PT, DPT, NCS, 
MPPA, director of clinical practice. “e fact 
that the people who teach in our clinical courses 
are still actively engaged in clinical care is a big 
dierentiator for us relative to many PT schools.” 
Students spend part- or full-time in the clinic 
with faculty during clinical rotations. 
With such strengths in research and the clinic, 
students come away with a strong foundation 
in movement system diagnoses. “is program 
has a rich history of mentoring and developing 
leaders in the profession,” Dunn said.
e program also shares its research and  
clinical advances through continuing education 
initiatives such as an upcoming APTA movement 
system summit. e summit joins together 
representatives from U.S. physical therapy 
programs to think about the movement system 
and how it can be implemented in curricula, 
research and practice.
“I think Washington University’s program 
will continue to be a leader as the movement 
system becomes more prominent on a national 
scale,” Earhart said. “And we have a lot of 
opportunity to help the public better understand 
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With increasing reports of superbugs that are  
resistant to virtually all antibiotics, experts warn  
of a return to the pre-antibiotic era. In that future, 
routine surgeries and minor conditions, such as a 
scraped knee or urinary tract infection, could more 
frequently result in serious infection or death. ose 
with impaired immune systems — including cancer 
and organ transplant patients — face the greatest risk. 
Proposals to address the problem call for  
judicious use of antibiotics, both by doctors and  
in U.S. agricultural practices. While overuse of 
antibiotics is a signicant contributing factor,  
experts say restrictive measures only will slow  
the problem. Bacteria, in a quest for survival,  
are continually adapting and mounting new,  
clever defenses against these drugs. 
Resistance
is inevitable
B Y  J U L I A  E V A N G E L O U  S T R A I T
Nature can  — and will — overcome any antibiotic.  
Researchers are working to ensure we stay one step ahead.
14  Washington University School of Medicine
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Microbiologist Gautam Dantas, 
PhD, is sequencing vast 
quantities of bacterial DNA 
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bacteria are products of other microbes, usually 
harmless organisms that live in soil. To survive, 
bacteria must prevent harm via their own chemical  
arsenals. Over millennia, microbes have evolved the 
capacity to produce these chemicals as part of 
their self-protection and communication strategies. 
“If you study old sources of soil bacteria that 
have no exposure to humans — microbes frozen 
in permafrost for millions of years, for example — 
some of these bacteria have genes that confer 
resistance to chemicals that we rely on as modern 
antibiotics,” Dantas said. 
With this history in mind, Dantas and 
colleagues sought to understand the extent of 
antibiotic resistance in current soil bacteria. 
Studying 18 dierent soil samples from across the 
U.S., the researchers concluded that soil bacteria 
contain a massive biochemical capacity to resist 
even our most potent antibiotics. However, they 
found that most of these genes fortunately are not 
poised to jump into bacteria that cause disease. 
Along with this presumably good news, the 
researchers made a worrisome discovery — a 
novel set of enzymes manufactured by soil 
bacteria that confer resistance to tetracyclines,  
a vitally important class of broad-spectrum 
antibiotics. e researchers also noted that these 
enzymes — which they dubbed tetracycline 
destructases — are coded into mobile parts of the 
bacterial genome that are easily shared, even 
between distantly related bacteria. It is mobile 
resistance genes that concern Dantas most. 
“We know such genetic transfers have already 
happened and will continue to happen,” Dantas 
said. “And we now have the tools to predict the 
chances that these bacteria will intermingle with 
microbes that cause disease, potentially transferring 
these resistance capabilities to the clinic.” 
Glimpsing the scope of microorganisms’ genetic 
capacity to evade antibiotics may be alarming, but 
in these vast databases of bacterial DNA, Dantas 
sees the blueprints for the design and development 
of new antimicrobial drugs. In theory, if you can 
determine how bacteria evade a specic drug, you 
can develop ways to thwart them. 
In one drug-development strategy, Dantas and 
associates are using genetic sequencing to identify 
and track the genes at highest risk of making 
disease-causing bacteria resistant to important 
antibiotics. e highest-risk genes — and Dantas 
puts the tetracycline destructases in this high-risk 
group — then become targets for the design of 
new compounds that inhibit these genes and  
their products. 
Microbiologist Gautam Dantas, PhD, argues that the only sustainable solution is to nurture a robust drug 
discovery pipeline. Informing his view is his lab’s 
extensive body of work documenting the genetics 
of antibiotic resistance in diverse environments, 
from hospital neonatal intensive care units, to 
rural farming villages, to urban slums, to an 
Amazonian tribe cut o from civilization. His 
overwhelming conclusion: Regardless of habitat, 
microbes are “chock-full” of DNA that gives them 
the capacity to survive chemical onslaught. 
“Resistance is inevitable,” said Dantas, associate 
professor of pathology and immunology. “No drug 
we design is going to permanently prevent resistance. 
e only way to ght resistance is to nd new drugs. 
And we have to do it continually. Microbes thrive 
everywhere, including miles below the Earth’s crust 
or surrounded by radioactive waste. 
“eir extreme versatility is a reminder that 
microbes can do incredible things,” he added. 
“ey have insanely large population sizes and can 
divide at incredible rates. What enables all this is 
incredible chemistry. Bacteria are the best chemists 
we know. We need to respect that ability.”
Antibiotics destroy or weaken bacteria in 
several dierent ways, including breaking up the 
cell wall, restricting replication and inhibiting  
the production of needed proteins. 
In an ever-escalating arms race, superbugs have 
accumulated genes that, in turn, interfere with 
antibiotics. ese strategies include pumping the 
drugs out of bacterial cells, blocking the drug 
from its target, and breaking apart the antibiotic 
molecules themselves. 
e notorious methicillin-resistant 
Staphylococcus aureus (MRSA), for example, 
destroys methicillin and similar drugs by breaking 
the drug’s key chemical bonds. In destroying the 
drug, MRSA protects not only itself but other 
bacteria nearby that lack such defenses. 
e concept of microbes as chemists is highlighted 
by the 1928 discovery of penicillin. Like penicillin, 
which is made by a type of mold, most antibiotics 
that people have harnessed to kill dangerous 
Microbes thrive everywhere, including 
miles below the Earth’s crust or  
surrounded by radioactive waste. 
16  Washington University School of Medicine




— and spread —
resistant bacteria
Interconnected ecological habitats make it easy for antibiotic resistance to spread. Resistant strains living in soil get passed 
on to humans through various routes. Gautam Dantas, PhD, and 
his team have studied diverse environments, including densely 
populated slums surrounding Lima, Peru, and a tiny subsistence 
farming village in El Salvador.  They uncovered numerous “hotspots” 
of resistance gene transfer, including chicken coops and sewage 
treatment systems. El Salvadoran villagers have close interactions 
with their chickens, giving the birds freedom to roam into cooking 
areas (below left). In Lima, sewage is processed in a wastewater 
treatment plant (center), and then the semi-clean gray water is  
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Indeed, tetracycline destructases’ genetic 
mobility and ability to destroy a drug widely  
used in the clinic and in agricultural settings  
have led Dantas to predict a major resistance 
problem in the future. Such resistance also could 
compromise new tetracycline-based drugs that  
are being considered for imminent clinical use. 
While such data sounds ominous, it also presents 
an unprecedented opportunity: the chance to 
design strategies to ght this type of tetracycline 
resistance before it begins circulating in hospitals.
“We are exceptionally reactionary in our 
response to antibiotic resistance,” Dantas said. 
“We only take action aer people have died.  
Until recently, we did not have the tools to 
determine where this resistance was coming from. 
Now, we understand that we live in interconnected 
habitats that harbor dierent kinds of bacteria. 
“We can track the genes that confer antibiotic 
resistance and begin to develop an understanding 
of how they move,” he added. “With that information, 
we can calculate the risk that they may transfer to 
bacteria that cause disease. is new understanding 
has led us to predict that the tetracycline destructases 
are at high risk of transferring to the clinic in  
the future.” 
e researchers’ argument was sucient to 
convince the National Institutes of Health (NIH) 
that tetracycline destructases are worthy of further 
research. Earlier this year, the NIH awarded a $3.6 
million grant to Dantas and collaborators Niraj 
Tolia, PhD, associate professor of molecular 
microbiology, and Timothy Wencewicz, PhD, 
assistant professor of chemistry. ey are working to 
develop inhibitors against tetracycline destructases.  
Such inhibitors could let tetracycline remain an 
eective antibiotic even if or (as Dantas argues) 
when bacteria carrying tetracycline destructases 
begin to emerge in health-care settings. 
Two are better than one
Because developing new inhibitors from scratch 
takes time, and patients are facing deadly 
antibiotic-resistant infections today, Dantas 
proposes a second strategy: high-throughput 
screening to test combinations of existing drugs. 
Attacking resistant bacteria using synergistic 
combinations of drugs can overwhelm defenses  
in ways that single drugs cannot.
Such “cocktails” that leverage drugs already 
approved by the Food and Drug Administration 
could, in theory, move more quickly into clinical 
use than novel compounds. 
Superbugs accumulate genes that interfere with antibiotics.  
These genes give microbes the ability to: (a) make impermeable  
cell walls; (b) block drugs from their targets; (c) break apart the drug 
molecules;  (d) pump drugs out; and, sometimes, all of the above.
Old drug, new tricks
Many approved antibiotics have been taken o the 
market because they are no longer eective. If new 
genomic strategies can be used to unravel the reasons 
an antibiotic has stopped working, compounds 
can be developed that target the resistance, rather 
than the bacteria. Once the resistance is knocked 
down, in theory, old drugs could work again. 
Tetracyclines are old drugs that are widely  
used in medicine, veterinary care and agriculture, 
especially in sh and shrimp farming operations. 
With such indiscriminate use, tetracyline 
resistance already exists in the clinic. But unlike 
MRSA, which destroys methicillin, tetracycline-
resistant bacteria in the clinic currently evade the 
drug without breaking it apart. Dantas worries 
that the prospect of bacteria carrying tetracycline 
destructases, which, as the name suggests, destroy 
tetracycline, may change that, elevating this type 
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Dantas’ team found that a combination of three 
drugs — meropenem, piperacillin and tazobactam 
— cleared mice of MRSA infections that normally 
kill them in less than a day. All three drugs belong 
to a class of chemicals called beta-lactams, 
considered obsolete against MRSA for decades. 
Dantas showed that the three drugs in tandem 
render the bacteria vulnerable to attack, making it 
dicult to resist the onslaught. If the bacteria 
become resistant to one component of the triple-
drug cocktail, they are rendered more sensitive  
to one or both of the others. 
“is is a parallel strategy to the tetracycline 
destructase story,” Dantas said. “In the rst case, 
we’re talking about studying ecology and genetics 
to design new inhibitors. In the second, we’re 
rescuing existing classes of antibiotics that are 
useless against certain bacteria when given 
separately. In both cases, we are anticipating the 
bacteria’s resistance strategies. at is our theme: 
When you go aer new treatments, think about 
resistance from the beginning.”
Lessons learned
Yearly in the U.S., antibiotic-resistant infections 
plague more than 2 million people, killing some 
23,000, according to the CDC. Dantas said these 
hard-fought battles oer lessons in how bacteria 
evolve resistance. 
In a third strategy, Dantas is working directly 
with hospital microbiology labs to sequence drug-
resistant infections as they emerge and identify 
how they evade antibiotics. “ere are a large 
number of emerging resistance strategies, and  
we just don’t know how they work,” Dantas said. 
Carey-Ann Burnham, PhD, is medical director 
of the clinical microbiology lab at Barnes-Jewish 
Hospital. She and Dantas are studying one 
particularly puzzling case in which a heart patient 
developed an infection that, in less than three 
weeks, became totally resistant to an important 
antibiotic called daptomycin. 
“e magnitude of the change in this bacteria’s 
ability to resist daptomycin had never been reported 
before,” Dantas said. “Typically, a bug might develop  
enough resistance that the dose would need to be 
increased two-fold or four-fold, for example. In 
this patient’s case, the dose would have needed to 
increase 1,000-fold to kill the bacteria.”
e patient survived, but only aer six weeks of 
treatment with linezolid, a toxic antibiotic of last 
resort. Courses longer than one month can cause 
serious complications, including bleeding and 
vision loss.  
To understand this particular superbug,  
Dantas and his colleagues are immersed in  
their molecular detective work. 
“We are excited to apply our knowledge and 
tools to help patients,” Dantas said. “We began by 
surveying bacteria in the environment, even 
though that work initially seemed far removed 
from any clinical application. But that research has 
helped us determined that resistance is everywhere. 
“Rather than seeking irresistible antibiotics, 
perhaps the best strategy is to treat resistance as a 
given, use our tools to anticipate where it will come 
from, and develop proactive strategies to address it 
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On top of mastering enormous volumes of material, 
sitting for exams, going through clinical rotations  
and applying for residencies, medical students don’t  
have a lot of spare time. 
Yet health-care professionals recognize the 
importance of research experience, even for students 
headed into clinical practice. Strong research skills  
and strong clinical skills are inextricably linked. 
Doctors must scrutinize an endless barrage of 
primary scientic literature; only by thinking  
critically can they determine the best course for 
individual patients.
At the School of Medicine, student research 
opportunities abound — in basic, clinical and 
translational science, global health, device and 
technology development, and in nearly every 
discipline. More than 2,100 faculty mentors stand 
ready to guide. 
Orchestrating the dizzying array of options and 
playing master project matchmaker between student 
and faculty mentor is Koong-Nah Chung, PhD, 
associate dean for medical student research. 
Learning
labs
B Y  D E B  P A R K E R
Outlook  21
For most medical students, there’s a major obstacle 
to doing research: being in medical school.
Not at Washington University.
Medical student Margery 
Gang collaborates on an 
acute myeloid leukemia 
project with Timothy  
Ley, MD, the Lewis T.  
and Rosalind B. Apple 
Chair in Oncology. 
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An upswing in involvement
Although involvement is optional, more than 95 
percent of students complete a research project 
during their time at the medical school.
“Research is an essential part of the MD 
curriculum,” said Michael M. Awad, MD, PhD, 
associate dean for medical student education and 
associate professor of surgery. “Here, they gain the 
ability to perform scientic discovery and begin a 
journey of lifelong learning, priming them to 
become future leaders in academic medicine.
 “Very few schools with optional research 
programs have such a high student participation 
rate, a fact noted positively during our recent 
medical school accreditation site visit,” he added.
e school’s robust research environment plays 
a key role in recruiting and molding students.  
Via in-house surveys, applicants cite “research 
opportunities” as one of the top two reasons for 
selecting Washington University. 
In surveys of U.S. medical students conducted 
by the Association of American Medical Colleges, 
Washington University respondents say they 
incorporate research into their studies at double 
the national rate. Further, they publish at twice  
the national rate. Sixty percent of Washington 
University medical graduates lands careers at 
academic medical centers versus 30 percent 
nationally. “We truly are training future 
physician-scientists,” Chung said.
Fieen years ago, just one-third of Washington 
University medical students participated in 
research, supported at the time by a small 
National Institutes of Health (NIH) grant.  
ere wasn’t a dean of student research or a 
centralized oce to coordinate project partnerships. 
Chung — who was appointed research assistant 
professor in 1996 and assistant dean in 1999 — 
became that point person and began advocating 
for increased participation. Five years ago, she 
formed the Oce of Medical Student Research. 
Chung and her team members, including 
coordinator Rosalyn Bradshaw-Robinson, and 
administrative assistant Heather Bartels, work 
tirelessly to create an infrastructure that spawns 
hundreds of research projects. To-dos include: 
soliciting funding; tracking the work of 2,000-plus 
principal investigators; and meeting one-on-one 
with students. e oce maintains comprehensive 
listings of trainees over the last 20 years and their 
funding sources and published works.  
 “She (Chung) is such a researcher at heart,” 
Bradshaw-Robinson said. “She attacks everything 
with such attention and detail.”
omas Baranski, MD, PhD, associate professor  
of medicine, agrees. “Dean Chung has been 
essential in fostering research opportunities for 
medical students. She has succeeded because of 
her own love of medical research and her passion 
to see our medical students get a chance to do 
their own research.”
In today’s competitive funding environment, 
only 7 percent of NIH grant submissions receive 
approval. However, Chung’s initial ve-year NIH 
grant from 2001 has been renewed four times, 
cumulatively bringing in $3 million for student 
research. As a result, every student participating 
in a summer research project has been fully 
funded for the past 16 years through this grant 
and nancial support from the dean’s oce.
is spring, Chung learned that the grant has 
been extended through 2021. e 1,200-page NIH 
grant application, which requires nine months of 
preparation, received a nearly perfect score.
Lengthier research projects are not fully covered, 
but Chung’s team leverages 20-plus funding 
mechanisms — including various foundations and 
private grants — and guides students in writing 
applications for nancial support.
Researcher at heart: 
Associate Dean Koong-Nah 
Chung, PhD, meets with 
every single student and 
tirelessly dedicates herself 
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For Chung, it all comes down to customer 
service. Seamless experiences for mentee and 
mentor boost participation and enrich the 
institution. “Denitely the word has gotten out,” 
Chung said. “Any medical student who wants to 
participate can. at commitment is loud and clear  
to students. If you want to do research, we make it 
easy here and you can do signicant research.”
To get the process started, Chung and Robinson  
meet personally with students. Because Chung 
also serves as admissions subcommittee chair, her 
mornings, October through February, are reserved 
for meeting prospective students. Her aernoons 
are spent helping current students better understand  
their interests as they seek meaningful projects.
As someone who knows all of the students and 
many of the faculty members, Chung strives to 
match temperaments. Finding an ideally suited 
mentor can forever alter a student’s life aspirations.
Rachel Goldberg, now a third-year medical 
student, met Chung during the admissions  
process and later sought her help in securing an 
otolaryngology research project. She echoes the 
thoughts of many students who describe Chung as 
one of the medical center’s most beloved members.
“Dean Chung is amazing,” Goldberg said.  
“She is one of the warmest people I know. She  
is what I thought about when I thought about 
Washington University. I don’t know anybody  
in the country who does what she does.”
For students on a hectic training path, this 
support makes all the dierence. “When I was 
looking at medical schools, I didn’t hear of 
another medical school that was able to provide 
that amount of funding to students,” Goldberg 
said. “I didn’t have to worry about nding funding 
for research. It denitely was a draw. I just needed 
to concentrate on my education.”
Pathways to 
research 
Washington University medical  
students conduct research through 
four options: 
Summer Research Program, a three-month  
introduction to research
Yearlong Research Program, in which 
students “stop the medical school clock” and 
are released from courses to conduct one 
year of in-depth research after their second 
or third year of medical school. Tuition is 
waived, and many students receive stipends.
Fourth-year elective, offering six to  
12 weeks of full-time, daily research for credit
Medical Scientist Training Program 
designed for physician-scientists who wish 
to earn a combined MD/PhD. The rigorous 
program takes six to eight years to complete; 
tuition is waived, and students receive an 
annual stipend. 
Medical students present their work 
at the annual poster session.
Outlook  23
‘We truly are  
training future  
physician-scientists.’ 
— Koong-Nah Chung, PhD
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“e most important part of being a mentor is 
listening to mentees, supporting them through 
their situation, whether that is a research project 
or personal life challenge,” Piccirillo said. “Now 
that I have been at the medical center for more 
than 20 years and have interacted with so many 
students, I feel very condent that I have valuable 
information to share. 
“I love to be available and help, when asked,  
for important decisions in our students’ lives,  
like specialty choice or whether to pursue an 
academic research career.”
Many such relationships evolve into decades-
long collaborative partnerships. “e mentor has 
the reward of witnessing the intellectual growth 
and maturation of the mentee,” said Michael 
Avidan, MBBCh, professor of anesthesiology and 
cardiothoracic surgery. “It is particularly 
rewarding when my students have advanced in 
their careers, developed their own research 
programs, and have demonstrated prowess as 
independent investigators.
“I believe that the most important contribution  
we make to society as faculty members is the 
mentorship and guidance we provide to our 
students.”
Stereotypes persist of the lonely scientist toiling 
away in a lab, performing repetitive tasks and 
interacting only with pipettes and test tubes.  
It’s Chung’s goal to dispel such notions and  
help students through their initial hesitation  
and self-doubt. Research, she said, is connected 
with independent thinking, creativity, teamwork 
and, most importantly, discovery. 
Lasting contributions 
Faculty here — including some of the world’s 
experts in their respective elds — are eager to 
welcome the 500 MD and nearly 600 PhD students. 
“Over the years, I’ve not had one faculty member 
who didn’t want to host,” Chung said. “We are 
successful because faculty are willing to mentor. 
I’ve also had support from Deans William Peck, 
Larry Shapiro and David Perlmutter and my 
mentors Ed Dodson and Leslie Kahl.”
For faculty, it’s inspirational to have smart, 
creative, hard-working students in their labs.  
“Our faculty are drawn here and retained here 
because of the ability to work with great students,” 
Chung said. 
Jay F. Piccirillo, MD, FACS, recalls the 
outstanding mentorship he received during 
fellowship training at Yale University from Alvan 
Feinstein, the grandfather of clinical epidemiology. 
Today, Piccirillo, a professor of otolaryngology-
head and neck surgery, enjoys serving a similar 
role in trainees’ lives and hopes to inspire them to 
become “change agents” in medicine.
Research opportunities extend 
from the bench to the bedside. 
Above, Alison G. Cahill, MD, 
MSCI (left), associate professor 
of obstetrics and gynecology, 
confers with medical student 
Fayola Fears about a research 
project focused on infant 
neurodevelopment. 
Many of the mentor-mentee 
relationships evolve into decades-
long collaborative partnerships. 
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Redefining medical practice 
Katherine Santosa admits she found the idea  
of research intimidating as a edgling medical 
student. is all changed following a mentorship 
with Susan Mackinnon, MD, the Shoenberg 
Professor of Plastic and Reconstructive Surgery 
and chief of the Division of Plastic and 
Reconstructive Surgery. 
“e decision to spend one year in the laboratory 
under Dr. Mackinnon has undoubtedly been one 
of the most important decisions I have made in  
my career,” Santosa said. 
“Dr. Mackinnon is a brilliant surgeon-scientist 
who generated research questions directly based 
on the challenges she encountered in the clinic 
and operating room,” she added. “en, she  
would take the data and translate the work from 
the laboratory back to her patients in the clinic.  
As a medical student, I witnessed the tremendous 
impact research could have on improving 
outcomes for surgical patients.”
Following a surgical residency at the  
University of Michigan, Santosa, MD, has 
returned to Washington University as a plastic 
surgery resident and research fellow under plastic  
surgeon Alison K. Snyder-Warwick, MD.  
Now, Santosa has new aspirations: to care  
for patients with facial paralysis and complex 
peripheral nerve injuries, and to have a  
laboratory that will improve understanding  
of neural regeneration. 
rough research, abstract concepts taught in 
the classroom become less elusive. Students gain 
an appreciation for the vigor of research — how  
to create hypotheses and test them and to 
meticulously record their work. Perhaps, most 
dauntingly, they learn about failure.
“In science, it’s a natural thing to encounter 
failure; it’s normal to encounter failure nine out  
of 10 times,” said Brian Kim, MD, assistant 
professor of medicine and dermatology. “For  
many students, especially students at great 
institutions like Washington University — to their 
credit — they haven’t oen encountered failure. 
It’s something all scientists have to tackle. I feel,  
as a PI, like much more of a coach than a teacher.
“It’s about having the right mentality and 
viewing science not as a sprint, but understanding 
that it’s a marathon and that we have to 
continuously put in the work,” he added. 
Santosa said research quickly taught her 
humility and resilience. “Designing experiments, 
getting presentations and publications accepted, 
and obtaining grants are all essential components 
of the process but they are exceedingly dicult to 
do,” she said. “While caring for patients certainly 
teaches you similar lessons, I think failure in 
research is more common than it is in the clinics, 
and the only way to succeed is to persevere.”
As part of the program, students must explain 
and defend their work in a poster presentation. 
is fall, the research oce will sponsor its 11th 
annual WUSM Research Symposium and Poster 
Session on campus. e event draws many 
inquiring minds from the medical center 
community. Students also are encouraged to  
travel and present at professional meetings.
Piccirillo said he was overjoyed to see the 
expression of personal pride and satisfaction on 
the face of one of his mentees — who suered 
from social anxiety — aer delivering a awless 
research presentation at a national meeting.
According to Kathryn Diemer, MD, assistant 
dean for career counseling and associate professor 
of medicine, such polished, prepared Washington 
University students fare well in the ercely 
competitive national residency match, earning 
coveted training spots. All of this leads to a 
generation of more knowledgeable,  
well-rounded physicians. 
As Chung says, “When given the tools, our 
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David H. Perlmutter, MD, executive 
vice chancellor for medical affairs 
and dean of the School of Medicine, 
talks with graduate research assistant 
Dolonchampa Maji in the new 4515 
McKinley Research Building. 
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David H. Perlmutter, MD, is closing in on his  
rst year as executive vice chancellor for medical 
aairs and dean of the School of Medicine. 
Originally from New York, Perlmutter has 
moved to St. Louis three times — rst as a medical 
student at Saint Louis University, then as a faculty 
member in pediatrics at Washington University, 
and now as dean. Most recently, he served as the 
Vira I. Heinz Endowed Chair of the Department 
of Pediatrics at the University of Pittsburgh and 
as physician-in-chief and scientic director of 
Children’s Hospital of Pittsburgh. 
Personalized medicine is No. 1 on his priority 
list, and he believes the School of Medicine is 
positioned to be a leader in the eld. 
Outlook  27
A leadership vision for advancing human health by  
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Tell us about your  
medical education at  
Saint Louis University. 
I didn’t realize my own potential for 
a long time. I thought I wanted to go 
to medical school and got into Saint 
Louis University, o the wait list. I didn’t  
unpack for six months because I didn’t 
think I would make it. But by the 
time I graduated, I had become a 
very dierent person. At graduation, 
I received so many awards that my 
family just couldn’t get over it; they 
thought I was a totally dierent 
human being. 
Basically, what had happened —  
and I didn’t fully realize this until years 
later — was that I had developed a love 
of medicine and of learning. It was 
in medical school, here in St. Louis, 
where I found that I could work with 
unbelievable capacity, discipline and 
focus and that I had an insatiable desire 
to learn more about physiology, biology 
and the medical profession overall. 
In 1983, you joined the 
Harvard Medical School 
faculty, but left for a position at 
Washington University. Why? 
At Harvard, I was extremely fortunate 
to work in Dr. Harvey Colten’s lab. 
He was a phenomenal scientist and 
mentor, and it was while working with 
him that I truly realized that biology 
was a key to understanding human 
diseases. When he took over as head 
of the Department of Pediatrics at 
Washington University in 1986, he 
asked me to come along. It might have  
seemed an odd decision — I didn’t 
have grant funding, my wife and I had 
a baby and another on the way, and  
I didn’t expect to go back to St. Louis 
— but I couldn’t say no, especially 
aer talking with the amazing people 
here. I met with Phil Needleman, 
Philip Stahl, Stuart Kornfeld, Je 
Gordon, Stan Korsmeyer and on and 
on. It was one giant aer another 
— and it wasn’t just this feeling of 
being surrounded by intellectual 
horsepower, there was a very evident 
feeling of nurturing and community. 
You come here and you become part 
of the community. When I set up my 
lab, I interacted with every single 
department and with investigators 
throughout the school. I became 
friends and colleagues with so  
many people who reached out to  
me. I loved it here.
After 30 years in medicine 
— first here and later at the 
University of Pittsburgh — 
what prompted you to return 
as dean? 
More than just one thing. St. Louis 
is a wonderful city and is dear to my 
family. One of the reasons I believe 
Washington University has such 
an incredibly successful medical 
school is because of the deep sense 
of community here. But also, there’s 
an uncommon level of support at the 
university for physician-scientists, 
and that was a major draw for me. 
e Medical Scientist Training 
Program here is the best in the 
world, and the physician-scientists 
are treasured in a way you don’t 
see anywhere else. Also, becoming 
dean meant I could play a role in 
making the changes and innovations 
that are so important to health care 
and biomedicine, and where better 
to be at the forefront of what is 
needed than Washington University? 
ere is so much going on here — 
in advancing science and curing 
diseases, in educating future doctors 
and scientists, and in providing 
excellent health care to people who 
need us. e commitment, energy 
and devotion you see here every day 
are incredible. 
Why are you focused on 
personalized medicine? 
Medicine treats many people in the 
same way, even though they have 
known dierences in the course 
of their diseases. e promise of 
personalized medicine is that we 
can become more sophisticated in 
our understanding of each disease, 
identify personal variations and tailor 
therapy to those variations in a way 
that is likely to be more eective. 
Many opportunities have arisen as 
genomic sequencing and editing 
have become more aordable, from 
developing new targets for drugs 
to speeding the diagnosis of life-
threatening illnesses. Simply put, the 
long-term objective is to give the right 
treatment to the right patient with the 
aim of saving and improving lives.  
There’s an uncommon level of support  
at the university for physician-scientists.
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The way I look at it, the biggest shot 
we have at reducing health-care costs 
is through our research.
How is Washington University 
positioned to be a leader in 
personalized medicine? 
ere are so many strengths at the 
university in the area of personalized 
medicine. We have centers for 
achieving dierent kinds of genetic 
sequencing here: a center that can  
help researchers reproduce a disease  
in a cell line or a mouse; a center 
where scientists can make induced 
stem cells; drug-focused centers  
that will help investigators zero in  
on therapeutics — the list goes on. 
Each of these many centers and  
the magnicent scientists who  
work in them are keys to tackling 
disease. I believe we need to continue 
focusing on the many areas where 
the university is an established leader 
and to develop core facilities that can 
rapidly incorporate new technology. 
Right now, for example, we have 
researchers working on personalized 
vaccines to treat breast cancer and 
melanoma. I believe we are at a  
tipping point for understanding 
human disease and improving  
patient care. Washington University 
is so well-positioned to advance 
knowledge and improve health and 
well-being. It is our responsibility  
to embrace this opportunity for  
the benet of society. 
How can personalized 
medicine improve the 
health-care system? 
If we can realize at least some  
parts of the dream of personalized 
medicine, we will be treating people 
in a much dierent way than we treat 
them today. Personalized medicine 
would allow us to provide a particular  
therapy only to patients it would help, 
sparing others from unnecessary 
treatments and harsh side eects. 
Meanwhile, other patients would 
receive therapy specic to them.  
So if only 20 or 30 percent of patients 
with, for example, breast cancer are 
receiving the most extensive and 
expensive therapy, that should reduce 
health-care costs and provide optimal 
care. e same approach could be 
applied to other diseases. And this  
is a great place to gure these things 
out because we have so much genomic 
expertise and tremendous investigators 
in cancer, immunology, the microbiome,  
Alzheimer’s disease, age-dependent 
degenerative diseases and other major 
areas of emphasis. 
e way I look at it, the biggest  
shot we have at improving medical 
care and reducing health-care costs is 
through our research. ere are many 
incremental ways to reduce such costs 
through process and changing how  
we do things. But what will really 
transform health care will come from 
research, and, for me, personalized 
medicine will be key.  
Dean Perlmutter with his wife, Barbara A. 
Cohlan, MD, a professor in the Department of 
Pediatrics specializing in newborn medicine. 
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What else would you like  
to see emphasized at the 
School of Medicine? 
I want to see discoveries benet 
our patients sooner, and I believe 
this will require more attention to 
commercialization. e genomic 
revolution has positioned us to move 
this forward in a more timely way, 
and the university is working hard 
to facilitate entrepreneurship in a 
most conscientious way. is school 
has always been noted for its great 
collaborations, but I also want to 
explore potential industry partners 
for shared research programs. 
Physician-scientist career 
development is also very important, 
particularly since the percentage 
of physicians nationally who are 
conducting research has been 
dropping in recent years. And 
another key emphasis for me  
will be diversity and inclusion 
throughout the Medical Campus, 
from students, to sta, to faculty. 
We need to improve diversity in our 
workforce in particular and become 
more successful at developing the  
careers of minorities. It’s so important 
to understand that we are richer as 
a whole with varying perspectives. 
Diversity and inclusion are imperative. 
I also want to continue building 
on our excellent faculty practice and 
improving our ability to serve the 
community. It’s an honor to provide 
exceptional health care to so many 
citizens throughout the St. Louis 
region and beyond. I’ve become very 
moved by how important our role is 
as a safety net. 
Now that you’ve been  
here nearly a year, what  
has surprised you most?  
I was surprised at some of the 
breathtaking science here. Even 
though I knew great things were 
going on at this school, I had no 
idea how extraordinary the breadth 
and the depth of the talent are 
and, likewise, how exciting the 
programs are. To a certain extent, 
it’s daunting because I see myself 
as being responsible for that now. 
It’s very humbling. But what’s 
exhilarating is that nobody here 
is going to be satised doing the 
same thing tomorrow that he or she 
is doing today. Everybody here is 
interested, like I am, in pushing the 
envelope and being at the forefront 
of new discoveries that ultimately 
will benet mankind. It’s an amazing 
place to be, and I’m so excited and 
fortunate to be a part of it. 
Nobody here is going to be satisfied 
doing the same thing tomorrow that 
he or she is doing today.
30  Washington University School of Medicine
Interview conducted and compiled by 
writer Elizabethe Holland Durando
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I n 1963, Tom Hornbein and Willi Unsoeld, fellow American mountaineers, became the rst climbers to summit the world’s highest 
peak — Mount Everest — via the dangerous 
West Ridge. Fiy years later, the climb is still 
hailed as one of the greatest achievements in 
mountaineering. Only 12 other climbers have 
ascended Everest by the West Ridge. Fourteen 
have died in the attempt. Hornbein, who was 
born in St. Louis and earned a medical degree 
from Washington University in 1956, addressed 
students at this year’s MD Commencement. 
Mountains remain a powerful metaphor in 
Hornbein’s life; they are the foundation on  
which he has based most of his major decisions. 
At age 13, Hornbein discovered the mountains 
during a summer camp in Colorado. He went on 
to major in pre-med at the University of Colorado 
and became involved in mountain rescue 
activities. Aer earning a medical degree back in 
St. Louis, Hornbein completed an anesthesiology 
residency at Barnes Hospital and a fellowship in the 
lab of pulmonary researcher Albert Roos (who died 
in 2007). Hornbein’s research focused on control  
of breathing by hypoxia, as at high altitude, and 
other physiological stimuli (CO2, pH) on 
peripheral and brainstem chemoreceptors. 
Folllowing the Everest climb, Hornbein 
joined the faculty at the University of 
Washington School of Medicine in Seattle 
and served as chair of the Department of 
Anesthesiology from 1978 to 1993. Now a 
professor emeritus, Hornbein and his wife, 
Kathy, live in Estes Park, Colorado. At 85, he 
still climbs the mountains around his home.
Hornbein advised students to view change 
and risk as essential ingredients for professional 
and personal growth. “As an anesthesiologist, 
most of the time I had great control,” Hornbein 
said. “Every now and then, things would bust  
loose. e ability to stand still, to think clearly 
in the middle of an emergency, to be a risk-
accepter and not risk-averse is critical. ... I wish 
you all grand adventures seasoned with a decent  
dose of uncertainty,” he said. 
Legend in climbing
Mountaineer-doctor shares wisdom gained from taking risks
Tom Hornbein, MD 
’56, delivered the MD 
Commencement  
address May 20. 
notable
Hornbein recounted his 
adventures in “Everest:  
The West Ridge.” A recently 
released 50th-anniversary 
edition includes photos by 
expedition members and 
a foreword by best-selling 
author Jon Krakauer.
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’Accept risk, savor it as an  
essential seasoning to becoming 
a good doctor, a good parent, a 
good you.’   — Tom Hornbein, MD ’56
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Washington University School of Medicine
  
has received a $10 million gi in support of the 
Andrew M. and Jane M. Bursky Center for  
Human Immunology and Immunotherapy Programs.  
Previously known as the Center for Human Immunology and 
Immunotherapy Programs (CHiiPs), the center is dedicated to 
understanding the immune system and its potential for treating 
cancer, ghting infection and providing novel treatments for  
autoimmune disorders and immune deciencies.  
 e gi from Andrew M. and Jane M. Bursky also  
supports an endowed distinguished professorship for the  
center’s director, Robert D. Schreiber, PhD, the inaugural 
Andrew M. and Jane M. Bursky Distinguished Professor. 
Harnessing immunity
A $10 million gift  
establishes Bursky  
Center for Human 
Immunology and 
Immunotherapy
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Harnessing immunity
“Andy and Jane’s generous gi will be used not only to 
support the innovative work of Dr. Robert Schreiber, but 
also to benet the distinguished team of researchers and 
physicians who are members of the center,” said Chancellor 
Mark S. Wrighton. “ese scientists are making incredible 
advances in the eld of human immunology.”  
Schreiber has led the center since its establishment in 
2014 with a focus on nurturing the translation of basic 
discoveries in the lab into new therapies for patients. Long 
known for its role in ghting infectious disease, the immune 
system has more recently been implicated in cancer and 
for its overactive role in autoimmune conditions such as 
rheumatoid arthritis, type 1 diabetes and multiple sclerosis.  
“With the strength of the immunotherapy programs at 
the School of Medicine combined with the sequencing power 
of the McDonnell Genome Institute, this new gi will help 
jumpstart major research initiatives in understanding and 
developing new immune-based therapeutics for a broad 
array of diseases,” Schreiber said.
New therapeutic strategies
Schreiber is well-known for his research in tumor 
immunology and cell signaling. His work has been 
instrumental in helping distinguish the conicting  
roles that the immune system can play in cancer, whether 
protective when preventing tumor growth or detrimental 
when unable to recognize and attack cancer cells. Fieen 
years ago, Schreiber and his colleagues introduced the 
three-phase concept of cancer immunoediting. In the rst 
phase, dubbed elimination, early cancer cells are destroyed 
by the immune system. ose cells that survive the initial 
onslaught then enter the second phase, termed equilibrium, 
characterized by a state of tumor dormancy. e nal 
phase — escape — occurs when the surviving tumor cells, 
now adept at evading the immune system’s defenses, escape 
the dormant state and begin to grow. New cancer immune 
therapies may focus on priming and retraining the immune 
system to once again attack these evasive cancer cells. 
Schreiber and collaborators at Washington University 
pioneered the use of genomics approaches to identify 
mutant proteins uniquely expressed in a patient’s tumor 
that can target the individual’s cancer cells for immune 
destruction. is approach has formed the basis for major 
ongoing translational programs at the School of Medicine 
and elsewhere to test the therapeutic ecacy of personalized 
vaccines in patients with cancers of the breast, brain, 
lung, pancreas, prostate, melanoma and certain forms 
of lymphoma. Beyond cancer research, other leading 
center investigators are studying important and emerging 
infectious diseases and viruses, including Zika, Ebola,  
West Nile and Chikungunya. 
e gi will enable an ongoing, coordinated eort to 
preserve blood and tissue from patients with various  
diseases that display immune system involvement. With 
patients’ permission, researchers will have access to blood 
and tissue samples before, during and aer treatment to 
study a patient’s native immunity and how it might respond 
to various therapeutic strategies. Such a resource could help 
doctors understand the reasons a specic immune therapy is 
eective in some patients but not others. 
“Jane and I are both honored and humbled that we have 
the opportunity to attach our names to the center, which we 
believe has enormous potential for scientic discovery and 
for improving the health, directly or indirectly, of the global 
community,” Andrew Bursky said. “e speed at which the 
center is translating ground-breaking discovery into new 
modalities of personalized treatment is incredibly exciting.  
We are very fortunate to be in a position to make a gi that 
can have a meaningful impact 
on the growth and impact of 
the center.”
Alumni give back 
Andrew Bursky is founder 
and chief executive ocer 
of Atlas Holdings LLC, an 
industrial holding company 
based in Connecticut. Bursky 
also serves as chairman of the 
company, which employs more 
than 23,000 people worldwide 
and operates in a variety of 
industries, including aluminum, 
automotive, building materials, 
construction, distribution, 
energy, paper and packaging. 
e Burskys have deep 
connections to Washington 
University, where Andrew 
earned bachelor’s and master’s 
degrees in economics and 
engineering and Jane earned a bachelor’s degree in French 
and education. Andrew Bursky serves as a university trustee 
and has received the School of Engineering’s Young Alumni 
and Alumni Achievement Awards and the School of Arts & 
Sciences Alumni Achievement Award. Together, they have 
provided scholarships for students, including establishing the 
Spirit of Washington University Scholarship. 
Andrew M. and Jane M. Bursky
Michael S. Diamond, MD, PhD, Robert D. Schreiber, PhD, 
and Wayne M. Yokoyama, MD, lead a team of investigators 








163262_32-39_MAD_cc15.indd   33 8/29/16   8:32 AM
34  Washington University School of Medicine Autumn 2016
Almost 
Alumni
As they transition to the 
next stage of their careers, 
graduating students reflect 
back on their medical journey.
Prior to Commencement, graduating students  in medicine, occupational therapy (OT) and physical therapy (PT) took time out to reect  
on their graduate education and write notes of friendly 
advice to incoming students. 
Sponsored annually by the Oce of Medical Alumni  
and Development, these “Almost Alumni” luncheon 
events give graduating students a chance to contemplate 
their new relationship with the medical school and  
dispense a little hard-won wisdom. 
Entering medical and physical therapy students 
found the notecards tucked inside their new white coats, 
presented during the white coat ceremonies in August. 
Occupational therapy students will receive their hand-
written messages in the fall.  
Here, six students share their thoughts as they  
transition to the next stage of their careers.
Graduating students 
dispense friendly advice to 
entering medical classes
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Lawrence Benjamin
MD 16
Benjamin is headed to Massachusetts  
General Hospital for an internal medicine 
residency. He advises new students to make 
time for friends and for themselves. “There 
will always be something you must study. 
However, you will not always have time to 
spend with friends. Prioritize your ‘me time,’ 
whether that is social or personal, and your 
four years will be so much more enjoyable.” 
Max Lustick
MSOT 16
Although excited to soon be doing fieldwork 
at a cancer rehabilitation institute in Salt Lake 
City, Lustick said he would miss friends, men-
tors and colleagues at Washington University. 
He advised: “Make as many connections as 
you can while you are here. You’ll never be 
around so many amazing people.” 
Tina Zhu
MD 16
Zhu is happy to be staying at Washington 
University for her internal medicine residency.  
“It’s exhilarating, seeing the results of my 
hard work,” she said. “I’m ready to move on 
to caring for my patients.” Zhu illustrated her 
welcome message with playful drawings  
of physicians holding stethoscopes, and 
encouraged new students to “work hard and 
stay focused, but make time to have fun.”
Amanda Smith
DPT 16
Smith is returning to her native Indiana as  
a pediatric physical therapist, and said  
she would miss all the friends she found in  
St. Louis. She described graduation as  
“surreal.” “You make lifelong friends here,  
and you’ll never all be in the same city  
again, so it’s a good idea to spend time 
together and make some memories.” 
Salma Hussain
OTD 16
Weeks before Commencement, Hussain could 
hardly believe that school was coming to an 
end. “I feel like the time went by very quickly,” 
she said. Hussain, who soon would begin  
her occupational therapy fieldwork at the 
Kennedy Krieger Institute in Baltimore,  
welcomed new medical school students, 
wishing them luck and “a wonderful first year.”
Rachael Humber
DPT 16
Humber’s next challenge: helping patients 
with movement impairment due to neuro-
logical events such as traumatic brain injury, 
spinal cord injury and stroke. “I get so excited 
seeing the recovery of patients. This is exactly 
what I wanted to do!”  Humber told new students 
to take full advantage of the opportunities 
they have been given: “Enjoy your time here, 
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1940 S 
Robert Gibb, MD 48, received the  
Dr. J. Richard Czajkowski Service Award 
from Puget Sound Blood Center and is 
president of the Western Pathologists 
Quality Assurance Association.
1950 S 
Lowell Gess, MD 51, an ophthalmologist, 
recently returned from Sierra Leone, in 
West Africa, where he worked with Ebola 
responders and researchers on the virus’s 
effects on eyesight. For 20 years, Gess and 
his family lived in Sierra Leone, opening 
an ophthalmology clinic, which is now 
known as the Lowell and Ruth Gess UMC 
Eye Hospital.
Max Heeb, MD 53, republished his  
autobiography “Max the Knife: The Life 
and Times of a Country Surgeon,” with 
three additional chapters.
Albert Diddams, MD 56, has retired from 
the U.S. Army and medical practice. He 
enjoys gardening, golf and spending time 
with his family.
Robert Froelich, MD 56, built and 
solo-flew a Lancair IV 300 mph carbon 
fiber aircraft. He enjoys flying and being 
a member of the Experimental Aircraft 
Association, United Flying Octogenarians 
and Aircraft Owners & Pilots Association.
1960 S 
Dale Heisinger, MD 66, is chairman of 
the San Juan County (Washington) Board 
of Health. He is also a proud husband, 
father and grandfather.
Emily Smith, MD 68, stepped down at 
the end of the 2015-16 fiscal year after 21 
years of dedicated service as the School of 
Medicine’s Annual Fund volunteer chair.
1970 S 
Laura Wexler, MD 71, recently left  
her position as senior associate dean  
to concentrate on clinical care at the 
Cincinnati Veterans Affairs Medical  
Center and medical student teaching  
at the University of Cincinnati College  
of Medicine. 
Linda Hershey, MD 76, has served as 
director of the dementia program at the 
University of Oklahoma Health Sciences 
Center since 2010. She planned to retire  
in June 2016.
1980 S 
David “Dave” Baltzer, HA 81, has been 
elected to a two-year term as president of 
the 963-member Missouri chapter of the  
American College of Healthcare Executives.
1990 S 
Madeleine De Reding Kraus, MD 91, 
moved to Orlando, Fla., to direct and 
expand the section of hematology  
and hematopathology at Nemours 
Children’s Hospital.
Maral Kibarian Skelsey, MD 91, is  
president of the Washington, D.C., 
Dermatologic Society and enjoys  
volunteering on the board of The 
Washington Ballet.
2000 S 
Kathryn Lindley, HS 11, a cardiologist at 
Washington University, has a keen interest 
in heart disease in pregnant women. She 
joined the faculty in mid-2014 and is work-
ing to establish a Women’s Heart Center, 
which, she envisions, will encompass ser-
vices from before pregnancy to end of life.
In Memory
A L U M N I
Virgil R. Bleisch, MD 48
Virgil R. Bleisch, a retired pathologist in 
St. Louis, died Saturday, Feb. 13, 2016.  
He was 92. Bleisch is remembered as a  
physician, scholar, researcher, teacher, 
soldier, mentor, adventurer, naturalist, 
gardener, musician, conversationalist and 
world traveler. He is survived by his wife, 
Nadya; sister, Grace; children and their 
Alumni assume new posts
Husband and wife Kevin A. Roth,  MD/PhD, HS ’89, and Robinna G. 
Lorenz, MD/PhD ’90, HS, have made 
numerous contributions to neuropa-
thology, immunology and medical  
education. With new positions, Roth  
and Lorenz are broadening their spheres 
of influence. In late 2015, Roth was 
named chair of the Department of 
Pathology and Cell Biology at Columbia 
University College of Physicians & 
Surgeons and pathologist-in-chief 
at New York-Presbyterian/Columbia 
University Medical Center. Before going 
to Columbia, Roth served as chair of 
the Department of Pathology at the 
University of Alabama at Birmingham 
(UAB) School of Medicine.
In early 2016, Lorenz was promoted 
to associate dean for physician scientist  
development at UAB School of Medicine,  
where she is also a professor of pathology  
and directs the UAB Medical Scientist 
Training Program and the Summer in 
Biomedical Sciences Undergraduate 
Research Program.
Autumn 201636  Washington University School of Medicine
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 Thomas G. Tape, MD ’81, 
FACP, has been 
named chair of 
the Board of 
Regents of the American College of 
Physicians (ACP). With more than 
143,000 internist members, the ACP is 
the largest medical specialty organiza-
tion in the U.S. The Board of Regents 
serves as its main policy-making body 
and manages ACP business and affairs.
Tape also is division chief of general 
internal medicine, vice chair for clinical 
affairs in internal medicine and professor 
of internal medicine at the University  
of Nebraska. His research focuses on 
health policy, physician judgment and 
decision making. As a member of a  
medical center task force, he provides 
health policy expertise to the  
Nebraska region.
Tape has served the ACP in many 
leadership capacities. His surveys of  
ACP physician members have been  
published in the Annals of Internal 
Medicine and the American Journal of 
Respiratory and Critical Care Medicine, 
and he co-edited the ACP book 
“Diagnostic Strategies for Common 
Medical Problems.”
Tape named American 
College of Physicians Chair
spouses William and Yunhua, Barbara and 
Dennis, Pamela and Timothy; grandchildren 
Ivan, Misha, Nicholas, Emily, Reva and AK; 
and nieces, nephews, great and great-great 
nieces and nephews and cousins.
Jeffrey Peter Cichon, MD 79
Jeffrey Cichon, an orthopedic surgeon 
in Las Vegas, died Wednesday, March 
30, after a hard-fought battle with 
pancreatic cancer. He was 62. Cichon 
graduated summa cum laude from Saint 
Louis University, completing a bachelor’s 
degree in chemistry in just three years. 
He earned a medical degree from WUSM 
and later completed a residency at Los 
Angeles County+University of Southern 
California Medical Center. Cichon became 
an associate professor at the University 
of Nevada School of Medicine, as well as 
an adjunct professor at Touro University. 
He trained and mentored many students 
who remember his commitment to treat-
ing patients not just with expert care, but 
with respect and compassion. Cichon is 
survived by his wife of 35 years, Vicki Lynn; 
children Jamie, Danielle and Nickolas;  
siblings John Cichon and Janelyn Wise; 
and his mother, Helen Cichon.
John Harsch, MD 83, HS 86
John Harsch, an internist in Henry County, 
Ga., died Wednesday, April 6, 2016, when 
he was struck by a car while cycling. He 
was 59. Harsch received bachelor’s and 
master’s degrees in physics from the 
University of North Carolina-Chapel Hill 
and a medical degree from WUSM. He went 
on to co-found Southeastern Primary Care 
Specialists. An avid soccer player, he trans-
ferred his passions to cycling and became 
an active member of Southern Crescent 
Cycling Club. Harsch is survived by his wife, 
Mary Carol; mother, Cecilia Jean; siblings, 
Donna Harsch and George Loewenstein, 
Dr. Alan and Wendy Harsch, Cecily and Paul 
Harsch-Kinnane, Douglas and Eden Harsch 
and Dr. Richard and Jennifer Harsch; and 
many nieces and nephews.
William Henry Martin, MD 58
William Henry Martin, a retired physician 
in Red Bluff, Calif., died Tuesday, March 
29, 2016. He grew up in hard times that 
included living in an orphanage for two 
years and developing an ear infection that 
resulted in hearing loss in one ear. Martin 
served in the military for four years after 
high school and was recalled during the 
Korean War. He would go on to complete 
a bachelor’s degree in three years from 
Arizona State University and a medical 
degree at WUSM. Martin was active at 
church and helped found the annual 
Kiwanis summer camp serving disadvan-
taged youth. He is survived by his wife of 
61 years, JoAnne, along with their four 
children, Gary, Judy, Linda and Karen;  
12 grandchildren; and brother David.
David Leon Rosenbaum, MD 60
David Rosenbaum died Wednesday, Dec. 
23, 2015. He is survived by his wife, Sandra, 
three children and six grandchildren.
Willard Daniel Rowland, MD 40
Willard Rowland, a pioneer in Oregon 
plastic and reconstructive surgery, died 
Tuesday, March 29, 2016, at his home in 
Lake Oswego, Ore. He was 101. Rowland 
completed undergraduate and medical 
degrees at Washington University, became 
a fellow at the Mayo Clinic in Rochester, 
Minn., and then served in the burns and 
reconstructive surgery division of the U.S. 
Naval Hospital in Bethesda, Md., during 
World War II. After the war, he helped 
open the plastic surgery unit at the 
Ochsner Clinic in New Orleans, La.,  
developing new emphases in children’s 
reconstruction. Rowland moved to 
Portland, Ore., to establish one of the first 
plastic surgery practices in the Pacific 
Northwest, where his work focused 
increasingly on children with congenital 
deformities, burns and other traumas. 
Later, he opened a second practice at 
the Eisenhower Medical Center in Palm 
Springs, Calif. He was predeceased by 
his parents; brother, James; and wives, 
Mary and Elynda. He is survived by his 
children, Willard D. Rowland Jr. (Susan 
Tannenbaum), Martha S. Rowland (Neil 
Marquis), Charles Rowland (Cathy), 
Anthony T. Rowland (Dolores) and Thomas 
H. Rowland (Pat Harada); and 10 grand-
children and 10 great grandchildren.
Maxine Scheibe, NU 66
Maxine Scheibe died Thursday, June 18, 
2015. Beloved wife of Robert Scheibe,  
HS, MD 64, LA 60, and friend of and  
scholarship donor to Washington 
University School of Medicine.
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H. Richard Tyler, MD 51, HS
H. Richard Tyler, a Harvard emeritus  
professor in neurology, died Sunday,  
May 8, 2016. He was 88. After graduating 
from Syracuse University in 1947, Tyler 
volunteered for the U.S. Army and served 
at the Los Alamos National Laboratory. He 
earned an MD from WUSM and completed 
a medical internship at the Peter Bent 
Brigham Hospital, now known as Brigham 
and Women’s, and a neurology residency 
at Boston City Hospital. After completing 
neurology fellowships at the Neurological 
Institute at Queen Square in London, the 
Salpetriere in Paris, and Johns Hopkins in 
Baltimore, he returned to Boston to join 
the faculty at Harvard Medical School, 
where he became the first full-time neu-
rologist at the Peter Bent Brigham Hospital 
and led the neurology division from 
1956-1988. He was appointed professor 
of neurology at Harvard Medical School 
in 1974 and became emeritus in 1999. His 
renowned collection of rare medical books 
was donated to the American Academy of 
Neurology Book Collection at Washington 
University. The 7,000-volume collection 
includes many landmark books in neurol-
ogy and neuroscience. He is survived by 
his wife of 64 years, Joyce; four children, 
Kenneth (Lisa), Karen, Douglas (Donna) and 
Lori Spisak (Ken); grandchildren Maxwell, 
Eric, Jason (Diane), Tanya (Matthew), 
Nathan (Katie), Elaine, Britta, Colby, 
Courtney, Hannah, Samantha, and Joe; 
eight great grandchildren and nephews.
F A C U L T Y
Hugh Chaplin Jr., MD
Hugh Chaplin Jr., a hematologist, research 
scientist and professor of medicine, died 
Friday, April 29, 2016. He was 93. Chaplin 
graduated from Princeton University 
and the Columbia University College of 
Physicians and Surgeons. While in college 
and medical school, he served in the U.S. 
Navy during the final months of World 
War II. He performed his internal medi-
cine residency at Massachusetts General 
Hospital and became chief resident. He 
entered an academic career through a 
research fellowship in the U.S. Public 
Health Service at the National Institutes of 
Health (NIH) and pursued additional train-
ing at the Medical Research Council Blood 
Transfusion Research Unit in London. He 
joined the WUSM faculty in 1955 and 
held several leadership roles, including 
as associate dean, director of the Irene 
Walter Johnson Rehabilitation Institute 
and director of the Barnes Hospital Blood 
Bank. Chaplin authored more than 140 
scientific articles and was recognized 
internationally for his work on sickle cell 
anemia, autoimmune hemolytic anemia, 
transfusion reactions and blood banking. 
In 2003, in honor of his longest-living 
sickle cell patient and research colleague, 
Chaplin self-published “Lenabell: A 
Doctor’s Memoir of a Remarkable Woman’s 
80-Year Battle With Sickle Cell Disease.” 
In his retirement, Chaplin worked exten-
sively for BJC Hospice in St. Louis, both 
as a volunteer visitor with the dying and 
as the organization’s pain management 
consultant. Chaplin is survived by his 
four children and their spouses, Kate and 
Roger Woodward, David and Jane Chaplin, 
Monique Chaplin and Mary McCartney, 
and John Chaplin and Jill Adams; and 
eight grandchildren and three great 
grandchildren. Chaplin was preceded 
in death by two beloved spouses, Alice 
Dougherty Chaplin, after 52 years of  
marriage, and Lee Nelken Robins, PhD, 
with whom he enjoyed 11 years of marriage. 
Mokhtar H. Gado, MD
Mokhtar H. Gado, for decades a leading 
researcher at Mallinckrodt Institute of 
Radiology (MIR) at WUSM, died Thursday, 
April 28, 2016. He was 84. Gado, a profes-
sor emeritus of radiology, was noted for 
his work with neurological diseases and 
conducted extensive research involving 
magnetic resonance imaging (MRI) of the 
brain and spine. He was recognized for  
his work regarding the radiological mani-
festations of Alzheimer’s disease and brain 
changes in the elderly, and in the correla-
tion of physical principles of magnetic  
resonance to the pathologic changes 
in the disease processes of the central 
nervous system. Over the years, Gado 
trained many of the nation’s top neurora-
diologists. Gado was born in Monoufiah, 
Egypt. He earned bachelor’s and medi-
cal degrees from Cairo University and 
completed internships and residencies at 
Cairo University Hospital, Addenbrooke’s 
Hospital in Cambridge, England, and 
what was then the National Hospital 
for Nervous Diseases, in Queen Square, 
London. He is survived by his longtime 
wife, Sonja Gado; children, Karim, Yasmine, 
Soraya and Ameer; brother, Kamel 
Hishmat Gado; and two grandchildren.
Morvarid Karimi, MD
Morvarid Karimi, a tenacious researcher, 
committed teacher and compassionate 
clinician in the Department of Neurology, 
died Saturday, May 21, 2016, of a brain 
hemorrhage. She was 44. An assistant 
professor in the department’s Movement 
Disorders Section, Karimi also had a joint 
appointment at Mallinckrodt Institute of 
Radiology. As a physician, she specialized 
in movement disorders, including dystonia 
and Parkinson’s and Huntington’s diseases, 
among other conditions, and conducted 
research in Mallinckrodt’s Neuroimaging 
Laboratories. In the lab, Karimi’s most 
recent research focused on dystonia and 
neuroimaging of dopamine pathways in 
the brain. Karimi also was respected for 
her attention to women’s rights, espe-
cially in the workplace. Born in Tehran, 
Iran, Karimi earned a medical degree in 
1999 from the University of Münster in 
Germany. She moved to the U.S., where 
she worked for a year at the Marshfield 
Clinic in Marshfield, Wis. Karimi com-
pleted a neurology residency through the 
University of Iowa in Iowa City, and landed 
at WUSM for a three-year movement dis-
orders fellowship. In 2007, she became an 
instructor of neurology and, in 2010, an 
assistant professor of neurology. Karimi 
is survived by her husband, Eric Johnson, 
MD, a hospitalist at Barnes-Jewish Hospital; 
son, Kian; daughter, Suri; parents, Ebrahim 
Karimi and Shahla Shahrokh; and brother, 
Ali Karimi. 
Marvin E. Levin, MD 51
Marvin Levin, a renowned endocrinologist 
and teacher for many years at WUSM, died 
Saturday, April 30, 2016. He was 91. Levin, 
a professor emeritus of clinical medicine, 
was an advocate for patients with diabetes. 
He specialized in the treatment of the  
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diabetic foot and helped start WUSM’s foot 
clinic. His goal was the prevention of lower 
leg and foot amputations in people with 
diabetes. He co-edited “The Diabetic Foot,” 
currently titled “Levin and O’Neal’s: The 
Diabetic Foot,” with Lawrence O’Neal, MD. 
The classic textbook has been published in 
several languages. Levin became professor 
emeritus in 1995, but continued serving  
the university through teaching and 
committee service. He earned bachelor’s 
and medical degrees from Washington 
University. Levin then completed a  
residency in medicine at Barnes Hospital 
and an endocrinology and metabolism  
fellowship at WUSM before joining the 
clinical faculty in 1955. He is survived by 
his wife of 40 years, Barbara; children,  
Lynn, Judy and Michael; and three  
grandchildren. His former wife, Gloria,  
is deceased.
Philip W. Majerus, MD 61
Philip W. Majerus, a renowned hematologist 
and professor emeritus of medicine at 
WUSM, died Wednesday, June 8, 2016. He 
was 79. Majerus is best known for research 
showing that low-dose aspirin prevents 
blood clots, reducing risk of heart attack 
and stroke. The discovery is credited with 
saving thousands of lives each year. Over a 
career spanning more than four decades, 
Majerus led research that describes the 
way blood clots. His work studying aspirin 
demonstrated that platelets play an active 
role in clotting, overturning the long-held 
idea that platelets were simply passive 
components of blood clots. The work 
on clotting led Majerus down additional 
pathways, resulting in an extensive body 
of work understanding the inositol system, 
which is involved in blood clotting but  
also has far-reaching roles in many other 
cellular functions. Majerus joined the 
WUSM faculty in 1966 as an assistant  
professor of biochemistry and of medicine. 
He became a professor of medicine in 
1971 and a professor of biochemistry in 
1976 and served on the medical school 
faculty until 2014, when he was named 
a professor emeritus of medicine. He 
earned a bachelor’s degree in science in 
1958 from Notre Dame University and his 
medical degree in 1961 from Washington 
University. He completed his internship 
and residency at Massachusetts General 
Hospital and then served as a research 
associate at what was then the National 
Heart Institute. Majerus was a member 
of the National Academy of Sciences, 
the Institute of Medicine, the American 
Academy of Arts and Sciences and the 
American Society for Clinical Investigation. 
He is survived by his wife, Elaine Majerus, 
MD, PhD, an associate professor of medi-
cine at WUSM; sisters Diane (Brick) Brewer 
and Kathy (Roby) Burke; daughters, 
Suzanne (Rodney) Thompson, Julie Del 
Valle and Karen Majerus; son, David (Cecily) 
Majerus; and four grandchildren.
Benjamin “Bud” Milder, MD 29
Benjamin Milder, a former faculty member 
in ophthalmology, died Monday, May 
16, 2016. Milder attended Washington 
University as an undergraduate and 
entered WUSM at age 19. He did an  
ophthalmology residency at the University 
of Chicago’s Billings Hospital, and worked 
at Hines VA Hospital during World War II as 
a major in the Army Medical Corps. After 
the war, Milder joined the ophthalmology 
faculty at WUSM and entered a private 
practice. He authored or co-authored 
numerous articles and medical texts, 
including the award-winning “The Fine 
Art of Prescribing Glasses Without Making 
a Spectacle of Yourself.” Milder was a 
frequent lecturer at medical conferences 
around the globe. He is survived by his 
wife, Jeanne Schieber; children, Michael 
(Sarajane) Milder, MD 70, Barry (Shelly 
Tobin) Milder, MD 73, Morton Milder, and 
Rabbi Laurence (Janet Elis) Milder; grand-
children, Jonathan (Marlene), Daniel,  
Kelly (Chad) Baldwin, Rabbi Rebecca 
(Ethan Bueno de Mesquita), Rachel  
(Adam) Lubchansky, Jacob (Julie, LA 03) 
Milder, LA 03, Miriam, Avi, and Alex; and 
10 great grandchildren.
Robert Charles Strunk, MD
Robert Strunk, a beloved and acclaimed 
pediatric allergist at WUSM, died Thursday, 
April 28, 2016. He was 73.  For almost 
three decades, Strunk, the Donald B. 
Strominger Professor of Pediatrics, worked 
in his lab, developing a productive  
clinical and research program for  
childhood asthma that significantly 
enhanced the understanding of the 
natural history of the disease and what 
triggers it. During those years, Strunk 
treated patients at St. Louis Children’s 
Hospital, where he was the inaugural 
director of the Division of Pediatric Allergy 
and Pulmonary Medicine. His research 
findings reflect the association between 
emotional well-being and chronic asthma. 
Additionally, Strunk’s research focused 
on a long-term interest in fatal asthma, 
including the disease’s role in children 
with sickle cell disease. For decades, 
Strunk followed children with asthma 
into adulthood as part of the Childhood 
Asthma Management Program, for which 
he was a director. Strunk also had active 
roles within the Pediatric Asthma Clinical 
Research Network and the Childhood 
Asthma Research and Education 
Network. Strunk earned a bachelor’s 
degree in chemistry, a medical degree 
and a master’s in biochemistry, all from 
Northwestern University. He completed 
a pediatric internship and residency at 
Cincinnati Children’s Hospital and then 
was drafted into the military. During the 
Vietnam War, he was a pediatrician at a 
naval hospital in Newport, R.I. Afterward, 
Strunk concurrently completed two  
fellowships in 1974, at Harvard Medical 
School and Boston Children’s Hospital. 
Besides clinical research and treating 
patients, Strunk proved pivotal in enlisting  
the National Institutes of Health (NIH) 
to support several national pediatric 
asthma initiatives. Improving the health 
of asthmatic children in economically 
disadvantaged neighborhoods was deeply 
important to him. Strunk was instrumental 
in establishing the Healthy Kids Express, 
a fully equipped and staffed mobile clinic 
that provides asthma care for children in 
underserved communities in Missouri. He 
is survived by his wife of 18 years, Juanita 
Strunk; two children, Chris Strunk and Alix 
Strunk; two stepchildren, Rick Macivor and 
Ellen Royal; and nine grandchildren. 
Submit Classnotes online: 
wumcnews.org/classnotes
163262_32-39_MAD_cc15.indd   39 8/29/16   8:32 AM
Advancing Health, 
          Transforming Lives
Great news! The law allowing tax-free charitable IRA gifts is now permanent.  
If you are age 70½ or older, you can reduce your taxable income by making tax-free 
gifts up to $100,000 each calendar year directly from your IRA to Washington  
University School of Medicine. Best of all, your gift will be used as you wish to  
support scholarships, professorships, research or another purpose you choose! 
Make a tax-free charitable IRA  
gift by year-end and:
n  Reduce your taxable income
n  Satisfy your required minimum distribution
n  Support the School of Medicine
 
 
Consult with your legal or tax adviser before making a charitable gift.
To learn more or notify us of your gift,  
contact the Office of Planned Giving at  
800-835-3503 or plannedgiving@wustl.edu.
To qualify:
n   You must be 70½ years of age or older when  
the distribution is made.
n   The transfer must go directly from your IRA to 
Washington University.
n   Your gift must be outright. Tax-free charitable IRA 
gifts cannot be used to fund a gift annuity, charitable  
trust, donor-advised fund or private foundation.
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John Harley, MD ’66, vividly recalls the “topping out” of the 
Gateway Arch on Oct. 28, 1965. Harley, then a fourth-year 
medical student, had heard that the 10-ton keystone — 
the final piece of the Arch — would be hoisted into place 
that day. He and several classmates looked for a high place 
on campus to watch the action. Queeny Tower was under 
construction, and the young men found an unattended 
service elevator. “We got out on the roof,” Harley said.  
“We could see the Arch with two giant cranes next to it.  
The cranes came in and put in the last piece.”  Harley 
graduated in 1966, and chose radiology as his specialty. 
He settled down in the Pacific Northwest, but he never 
forgot that moment. “We knew that we were witnessing 
a piece of history,” he said. Harley returned to the School 
of Medicine this May to celebrate his 50th Reunion. While 
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Alumni advice
This past spring, soon-to-be graduates 
took time to reflect and write some 
notes of friendly advice. Entering 
students found the notecards tucked 
inside the pockets of their new white 
coats, which they received during the 
White Coat ceremonies in August.  
See story, page 34. 
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